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Abstract Degradation of the large cartilage proteoglycan ag- 
grecan in arthritis involves an unidentified enzyme aggrecanase, 
and at least one of the matrix metalloproteinases. Proteinase- 
sensitive cleavage sites in the aggrecan interglobular domain 
(IGD) have been identified for many of the human MMPs, as well 
as for aggrecanase and other proteinases. The major MMP ex- 
pressed by chondrocytes stimulated with retinoic acid to degrade 
their matrix is collagenase-3 or MMP-13. Because of its poten- 
tial role in aggrecan degradation we examined the specificity of 
MMP-13 for an aggrecan substrate. The results show that 
MMP-13 cleaves aggrecan in the IGD at the same site (..PEN341- 
FFG..) identified for other members of the MMP family, and also 
at a novel site ..VKPas4-VFE.. not previously observed for other 
proteinases. 
Key words: Aggrecan; Matrix metalloproteinase; Collagenase; 
Arthritis; Cartilage degradation 
1. Introduction 
Aggrecan is the major proteoglycan found in cartilage and 
it is the structural molecule that contributes most significantly 
to the weight-bearing properties of the tissue. A major feature 
of cartilage degeneration associated with arthritis is loss of 
aggrecan due to proteolytic leavage within the interglobular 
region between the G1 and G2 globular domains. The pro- 
teinase(s) responsible for aggrecan degradation i  the tissue 
have not been identified, but much interest has focused on the 
role of the matrix metalloproteinases in arthritic disease [1-10]. 
A predominant MMP cleavage site in the aggrecan interglobu- 
lar domain has been identified between N341 and F342. The 
stromelysins, collagenases, gelatinases, and matrilysin are all 
active at this site [11-14]. MMP cleavage at N341 F342 produces 
aggrecan fragments with N-terminal FFGVG... sequence and 
there is evidence for cleavage at this site in vivo [12,15]. Prod- 
ucts of cleavage at this site have also been identified in culture 
medium from unstimulated porcine cartilage xplants [16] and 
in synovial fluids from arthritis patients [17]. 
The major aggrecan fragments found in human synovial flu- 
ids from OA and joint injury patients however, do not corre- 
spond with MMP cleavage products, but rather result from 
cleavage at the E373-A374 bond in the IGD [18,19]. Similarly, 
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under conditions of normal and IL-1 stimulated turnover carti- 
lage explants release aggrecan fragments with N-terminal se- 
quences corresponding to cleavage between E373 and A374 [20- 
22]. The putative nzyme responsible for this cleavage has been 
named aggrecanase but its identity remains unknown. Sites in 
the IGD that are cleaved by cathepsin B [13], leukocyte lastase 
[23], plasmin and urokinase [24] have also been described, but 
do not correlate with aggrecanase cleavage. Interestingly, one 
member of the MMP family, MMP-8, has been shown to have 
aggrecanase activity in vitro [25]. 
Collagenase-3, or MMP-13, was recently cloned from a 
CDNA library derived from a human breast urnout [26] and 
shown to contain structural motifs that identify it as a new 
member of the collagenase subfamily of MMPs. MMP-13 ex- 
hibits 86% homology in amino acid sequence to rat and mouse 
MMP-1 [27,28] suggesting that rodent collagenase and human 
MMP-13 represent a gene product hat is distinct from MMP-1 
[28]. MMP-13 is also the major MMP expressed by retinoate- 
stimulated chondrocyte monolayers [29]. Because of its poten- 
tial role in aggrecan degradation it was of interest to examine 
the specificity of this new MMP for an aggrecan substrate. Our 
results show that MMP-13 cleaves the aggrecan IGD at the 
same major (..PEN34t-FFG..) and minor (...SED44t-LVV...) 
MMP cleavage sites identified for other members of the MMP 
family, and also at a novel site, ..VKP3s4-VFE.., not previously 
observed for other proteinases. 
2. Materials and methods 
An enhanced chemiluminescence (ECL) Western blotting kit, cyste- 
ine proteinase inhibitor E-64 and pepstatin were from Boehringer 
Mannheim, Germany. Keratanase (Pseudomonas sp.) (EC 3.2.1.103), 
keratanase II (bacillus sp.) and chondroitin ABC lyase (Proteus vul- 
garis) (EC 4.2.2.4) were from Seikagaku Kogyo, Japan. Agarose type 
HSC was from PS Park Scientific (Northampton, UK). Trypsin 
(diphenylcarbamoyl chloride treated) (EC 3.4.21.4), soybean trypsin 
inhibitor, 1,10-phenanthroline, 3-dimethylaminopropionitrile, 6-ami- 
nohexanoic acid, phenylmethanesulphonyl fluoride, benzamidine 
hydrochloride and 4-aminophenylmercuric acetate (APMA) were from 
Sigma Chemical Co. (St. Louis, MO). [4-(2-Aminoethyl)benzene]- 
sulfonylfluoride (AEBSF) was from Calbiochem-Novabiochem, Aus-
tralia. Human umbilical chord hyaluronan was from BDH (Poole, 
Dorset, UK). A Biosep-SEC $4000 hplc column (300 x 7.8 mm) was 
from Phenomenex, USA. Rabbit anti-mouse horseradish peroxidase 
(HRP) conjugated immunoglobulin was from Dako (Denmark) and a 
goat anti-mouse-HRP conjugate was from Promega Corporation (Aus- 
tralia). Polyvinylidene difluoride membrane (Immobilon) was from 
Millipore-Waters (Sydney, Australia). All other reagents were of 
analytical grade. 
2.1. Expression of recombinant MMP-13 
Human recombinant procollagenase-3 was expressed using stably 
transfected NSO mouse myeloma cells and purified from serum-free c ll 
culture medium using S-Sepharose fast flow (Kn~iuper t al., 1995, 
submitted). 
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2.2. Enzyme digestions 
MMP-13 digestions were in buffer containing l0 mM calcium chlo- 
ride, 100 mM sodium chloride, 50 mM Tris-HCl, pH 7.5, at 37°C, for 
the times specified. The digests also contained 1.25 mM AEBSF, 5 ¢tM 
pepstatin and 20/~g/ml E64 as proteinase inhibitors. G1 G2 samples 
were keratanase-treated prior to SDS-PAGE. Keratanase digestions 
were in 50 mM Tris/acetate buffer, pH 7.2, at 37°C overnight with 0.025 
units of keratanase/30/11, in the presence of 10 mM EDTA, 20/lg/ml 
E64, 5 /IM pepstatin and 1.25 mM AEBSF. For sequencing experi- 
ments, a high concentration (160/lg/ml) of MMP-13 was used and I84 
/lg purified G1 G2 was digested for 16 h at 37°C. The digestion prod- 
ucts were then mixed overnight with hyaluronan and purified on a 
Biosep-SEC $4000 hplc column [13] and sequenced directly from immo- 
bilon membranes following SDS-PAGE and electrotransfer. 
2.3. Activation of pro-MMPs 
ProMMP-13 (244/dg/ml) was activated with either 1 mM APMA for 
2 h at room temperature in a total volume of 62.5 ,ul, or 1 /dg trypsin 
for 5 min at 37°C in a total volume of 46 ,ul. Trypsin was inactivated 
with 12.5/~g of soybean trypsin inhibitor. 
2.4. Irnmunodetection with monoclonal antibodies AF-28 and BC-3 
Samples electrophoresed on 5% SDS gels [30] or agarose/acrylamide 
composite gels [31] were transferred onto Immobilon membrane and 
analysed for AF-28 epitope [17] or BC-3 epitope [32]. After blocking 
with 5% skim milk powder in PBS, the membranes were incubated with 
AF-28 antibody (1 : 1,000 dilution) or BC-3 antibody (1 : 1,000) in 0.5% 
skim milk powder in PBS for 1 h at room temperature then washed six 
times in buffer containing 0.1% tween-20 in PBS. Membranes for AF- 
28 detection were incubated for a further one hour with the Dako 
anti-mouse-HRP conjugate (1 : 10,000 dilution) at room temperature in 
0.5% skim milk powder in PBS and membranes for BC-3 detection were 
incubated with the Promega nti-mouse-HRP conjugate (1 : 7,500 dilu- 
tion). After six washes in PBS with 0.1% tween-20 the membranes were 
treated with ECL reagent according to the manufacturers instructions. 
Prior to immunodetection with BC-3 antibody, glycosaminoglycan 
chains present on whole aggrecan (but not G1-G2) were removed by 
digesting the membranes with 0.01 U/ml chondroitin ABC lyase, 0.01 
U/ml keratanase and 0.001 U/ml keratanase 11 in 50 mM Tris/Acetate 
pH 7.4 for 2 h at room temperature [32]. 
3. Results 
3.1. MP-13 activation by APMA or trypsin 
ProMMP-13 was activated with either APMA or trypsin to 
determine which activation procedure gave the maximum 
amount  of proteinase activity (Fig. 1). The results show that 
trypsin-activated enzyme was more active than APMA-act i -  
vated enzyme against an aggrecan G1 G2 substrate, since 1.4 
/~g/ml APMA-act ivated MMP-13 failed to degrade G1 G2, 
whereas 1.4/~g/ml trypsin-activated MMP-13 gave abundant  50 
kDa G1 product and 85 kDa G2 product. When a twenty-lk~ld 
higher concentrat ion of enzyme was used, G1-G2 was almost 
completely degraded by APMA and trypsin-activated nzyme 
although a small amount  of undigested substrate still remained. 
At 28 ¢tg/ml, trypsin-activated enzyme, but not APMA-act i -  
vated enzyme, produced a small amount  of a 68 kDa band 
(Figs. 1 and 3, arrow). These results indicate that trypsin treat- 
ment yields a more active MMP-13 than APMA,  and trypsin 
activation was used for all subsequent experiments. There was 
no difference in the pattern or ratio of bands produced by 
MMP-13 digestion when the digests were done at pH 5.5 (re- 
sults not shown). 
3.2. Digestion o f  aggrecan with MMP-13  
To determine whether MMP-13 would cleave aggrecan at the 
major ..PEN341-FFG.. site identified for other MMPs,  whole 
aggrecan purified from human, pig, calf, rat and shark cartilage 
~oo~ eb trypsin aAPMA°n activati°n MMP-13 
II 1.4 28 
I 
1 2 3 4 5 
Fig. 1. Purified G l-G2 (2.5 ,ug) was digested with 1.4,ug/ml (lanes 2 and 
4) or 28/tg/ml (lanes 3 and 5) of MMP-13 which had been activated 
with either APMA (lanes 2 and 3) or trypsin (lanes 4 and 5). Aliquots 
of digested (lanes 2-5) and undigested (lane 1) G1-G2 were electro- 
phoresed on 5% SDS gels and visualised with silver stain. 
was digested and analysed on dissociative agarose/acrylamide 
composite gels. MMP-13 digestion of all the mammal ian aggre- 
cans (Fig. 2a) and the shark aggrecan (not shown) generated 
products of faster electrophoretic mobil ity as seen by toluidine 
blue staining. Immunodetect ion with monoclonal  ant ibody 
AF-28, specific for cleavage at the major MMP site which 
creates the neo-epitope FFGVG. . .  N-terminal sequence [17], 
revealed specific staining in MMP-13-digested aggrecan from 
human, pig, bovine and rat aggrecan (Fig. 2b), but no AF-28 
immunoreactivity was detected with the shark substrate, sug- 
gesting that the . .D IPENFFGVG. .  sequence is absent or mod- 
ified in this primitive species. The . .D IPENFFGVG. .  sequence 
is not found in avian aggrecan [33]. No AF-28 immunoreactiv- 
(a )  Totuidine 
b lue  
(b)  AF-28 
b lo t  
Pig Human Ca l f  Rat 
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1 2 3 4 5 6 7 8 
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Fig. 2. Aggrecan (640 ,ug/ml) purified from human, pig, calf, and rat 
chondrosarcoma c rtilage was digested overnight with 0.5/lg/ml tryp- 
sin-activated MMP-13. Aliquots of digested (lanes 2, 4, 6 and 8) and 
undigested (lanes 1, 3, 5 and 7) material were electrophoresed in dupli- 
cate on agarose/acrylamide composite gels. Based on their dye-binding 
content, 5¢tg of sample was loaded for toluidine blue staining (a) and 
1 /~g was loaded for AF-28 immunoblotting (b). 
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(a) Silver stain (b) AF-28 blot 
Fig. 3. Purified G1-G2 (106 ,ug) was digested with 148 pg/ml trypsin- 
activated MMP-13, followed by keratanase digestion and the pattern 
of digestion analysed on 5% SDS gels by silver staining (a) and AF-28 
immunoblotting (b). The G 1 and G2 globular domains are represented 
schematically. The FFG.. N-terminal sequences (determined experi- 
mentally) and the..SED C-terminal sequences (predicted [17,25,45]) are 
also shown schematically. The unlabelled arrow indicates the band 
analysed by sequencing. 
ity was detected in undegraded aggrecan as reported previously 
[17]. These results how that MMP-13 shares the same specific- 
ity for the ..PEN341-FFG.. cleavage site in aggrecan as other 
members of the MMP family. Immunoblotting with monoclo- 
nal antibody BC-3, which recognises the neo-epitope created by 
cleavage at the aggrecanase site, did not reveal any im- 
munoreactivity ndicating that low concentrations of MMP-13 
(0.5 pg/ml) did not cleave at the E373-A374 aggrecanase ite in 
any of these species. 
3.3. Digestion of G1-G2 with MMP-13 
An aggrecan G1-G2 substrate [34] was digested with a high 
concentration of MMP-13 (160/~g/ml) to determine whether 
this enzyme was able to cleave at the aggrecanase ite in the 
IGD. The pattern of digestion products was analysed by SDS- 
PAGE with silver staining, or Western blotting with monoclo- 
nal AF-28 or monoclonal BC-3. Three MMP-13 digestion 
products were detected by silver stain (Fig. 3a). The large G2- 
containing product (Mr approximately 85kDa) and the fastest 
migrating G1 product (Mr approximately 50 kDa) have been 
identified previously [17] by sequencing [11,25] and im- 
munoblotting [11]. The middle band was of a similar size to the 
75 kDa aggrecanase fragment produced by MMP-8 digestion 
[25]. However, immunodetection with BC-3 monoclonal anti- 
body, specific for the N-terminal ARGSVI.. sequence gener- 
ated by cleavage at the aggrecanase ite, was negative, indicat- 
ing that even at high concentrations MMP-13 failed to cleave 
at the aggrecanase ite. The identity of this band was therefore 
determined by N-terminal sequence analysis (see below). 
AF-28 immunoblotting of the MMP-13 digested G1 G2 
showed two products (Fig. 3b). The largest band represents he 
same 85 kDa G2 band that was detected by silver stain (Fig. 
3a). A significantly smaller proportion of AF-28 epitope was 
present on a band of approximately 68kDa. Based on its size 
and N-terminal sequence, this band is most likely to corre- 
sponds with a fragment derived from the interglobular domain 
that is the product of cleavage at both the major and minor 
MMP sites ([17], fragment 6). As shown in Fig. 4, a minor 
activity of interstitial nd neutrophil collagenases [14] and ma- 
trilysin [13] is cleavage at the minor MMP site. This action 
produces a 68 kDa IGD product similar to that seen in Fig. 3b, 
as well as a smaller 40 kDa G2 product ([17], fragment 4) with 
an LVVQV.. N-terminal sequence [14,25]. The MMP-13 di- 
gests, however, did not show any 40 kDa G2 band on the silver 
stain (Fig. 3a), even though the enzyme appeared to have 
cleaved at the minor MMP site. One explanation for this is that 
the proportion of substrate cleaved at the minor MMP site was 
very low (based on the relative intensity of the two AF-28 
bands; Fig. 3b). The relative abundance ofthe two AF-28 bands 
suggests that cleavage at this site is also a minor activity of 
MMP-13. A second explanation is that silver stain is signifi- 
cantly less sensitive than immunoblotting (based on the relative 
intensity of the 85 kDa G2 bands in Fig. 3a,b), and the amount 
of the 40 kDa G2 band was too low to detect by this method. 
3.4. N-terminal sequence analysis" of an MMP-13 digestion 
product 
N-terminal sequencing of the unknown band identified on 
the silver-stained gel (Fig. 3a) revealed a VAL-PHE-GLU-xxx- 
xxx N-terminal sequence corresponding to MMP-13 cleavage 
at ..VKP384 ~ VFE.. (Fig. 4). This novel cleavage site in the 
aggrecan IGD has not been reported previously for any pro- 
teinase. 
4. Discussion 
The report by Flannery and Sandy [29] that MMP-13 is the 
predominant MMP expressed by chondrocytes under condi- 
tions of accelerated matrix resorption, raises important ques- 
tions about the role of MMP-13 in normal and pathological 
aggrecan catabolism. Recent data has shown that in addition 
to the predominant involvement of aggrecanase [18,19,35], 
there is also a significant involvement of one or more MMPs 
in aggrecan degradation. MMP inhibitors can specifically block 
release of aggrecan from resorbing cartilage [16,3638] but 
more compelling evidence for the involvement of MMPs in 
cartilage degradation is that N- and C-terminal aggrecan eo- 
epitope sequences, derived specifically from MMP activity, 
have been found in cartilage [12,15,39] and synovial fluids [l 7]. 
Since MMP-13 shares the same sequence specificity for an 
aggrecan substrate as other members of the MMP family, it 
must be considered as one of the candidate mediators of aggre- 
can degradation. 
This study has identified a new cleavage site in the IGD. 
Cleavage between P384 and V385 in aggrecan has not been re- 
ported previously. Peptide bond cleavage at proline residues 
occurs during MMP-8 [40] and MMP-1 [41] autoproteolysis at 
P250 I25~ and Pe47-I248, respectively. Interestingly MMP-13 does 
not cleave after proline in the hinge region, but at 8245-L246 
~T~6fMMPi !AggrecaHase M)norM'M'P1 
Fig. 4. Schematic representation f a non-continuous amino acid se- 
quence in the aggrecan IGD showing the major MMP site that is 
cleaved by all MMPs, the aggrecanase site [20 22], the minor MMP site 
that is cleaved by matrilysin [13] and the collagenases [14,25] and addi- 
tional minor sites that have been identified for MMP-3 [25] and MMP- 
13. 
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(Knfiuper and Murphy, unpublished results). MMP-7 [42] and 
MMP-8 [43] have also been shown to cleave between proline 
and methionine residues. The cleavage at P384-V385 in aggrecan 
is clearly a minor activity of MMP-13 since high enzyme con- 
centrations are required for cleavage at this site to occur. This 
is similar to the finding that, in vitro MMP-3 and MMP-8, at 
high concentration or in the presence of polyethyleneglycol, 
exhibit additional minor activities, cleaving at 8377 V378 and 
E373-A374, respectively [25]. The in vivo significance of these 
minor MMP actions is not clear; there is no direct evidence in 
vivo for cleavage at sites in the IGD other than at the major 
MMP site and the aggrecanase ite. However some studies have 
shown that at least seven different G1 fragments can be found 
in human articular cartilage xtracts [44], suggesting that there 
are probably multiple and complex catalytic processes contrib- 
uting to the net loss of aggrecan from cartilage. 
There are currently no clues as to which of the MMPs in 
cartilage may be involved in aggrecan degradation. There is no 
way of discriminating between the actions of individual MMPs 
on the basis of their degradation products. Discrimination of 
this kind awaits the development of inhibitors highly specific 
for a single MMP. Similarly the presence of high levels of MMP 
MRNA in joint tissues may not be reflected in high levels of 
translated enzyme, and high levels of pro-enzyme may not 
result in high catalytic activity if the enzyme remains in its 
inactive pro-form. Thus the identity of the MMP(s) involved 
in aggrecan degradation and its mechanism of action relative 
to the putative aggrecanase enzyme is still to be resolved. 
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